Barclays Reaffirms “Buy” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Barclays restated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report issued on Thursday morning, AnalystRatings.com reports. The firm currently has a $182.00 target price on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of several other reports. HC Wainwright reiterated a hold rating and issued a $147.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 8th. ValuEngine raised Jazz Pharmaceuticals from a strong sell rating to a sell rating in a research note on Wednesday, October 2nd. Zacks Investment Research cut Jazz Pharmaceuticals from a buy rating to a hold rating and set a $138.00 price objective on the stock. in a research note on Friday, September 13th. Wells Fargo & Co reissued a buy rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 14th. Finally, BidaskClub cut Jazz Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, October 11th. Two analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $165.71.

Shares of NASDAQ JAZZ traded up $0.74 during midday trading on Thursday, hitting $130.88. The company’s stock had a trading volume of 427,184 shares, compared to its average volume of 551,364. The company has a current ratio of 3.71, a quick ratio of 3.52 and a debt-to-equity ratio of 0.58. The business’s 50 day moving average is $124.79 and its two-hundred day moving average is $131.73. Jazz Pharmaceuticals has a 12-month low of $113.52 and a 12-month high of $154.44. The firm has a market cap of $7.24 billion, a P/E ratio of 10.69, a price-to-earnings-growth ratio of 1.57 and a beta of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, topping the consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a return on equity of 28.57% and a net margin of 29.61%. The firm had revenue of $537.70 million for the quarter, compared to the consensus estimate of $523.92 million. During the same period in the prior year, the business posted $3.58 earnings per share. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals will post 13.54 earnings per share for the current fiscal year.

In related news, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total value of $65,000.00. Following the transaction, the chief executive officer now owns 311,855 shares of the company’s stock, valued at $40,541,150. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.30% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its position in Jazz Pharmaceuticals by 28.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,555,801 shares of the specialty pharmaceutical company’s stock valued at $364,355,000 after acquiring an additional 562,700 shares in the last quarter. Nuveen Asset Management LLC boosted its position in Jazz Pharmaceuticals by 4,979.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,924,270 shares of the specialty pharmaceutical company’s stock valued at $274,324,000 after acquiring an additional 1,886,384 shares in the last quarter. Boston Partners boosted its position in Jazz Pharmaceuticals by 2.7% during the 2nd quarter. Boston Partners now owns 1,341,023 shares of the specialty pharmaceutical company’s stock valued at $191,116,000 after acquiring an additional 35,360 shares in the last quarter. LSV Asset Management boosted its position in Jazz Pharmaceuticals by 12.5% during the 2nd quarter. LSV Asset Management now owns 1,127,120 shares of the specialty pharmaceutical company’s stock valued at $160,682,000 after acquiring an additional 125,470 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in Jazz Pharmaceuticals by 46.9% during the 2nd quarter. AQR Capital Management LLC now owns 1,057,019 shares of the specialty pharmaceutical company’s stock valued at $147,496,000 after acquiring an additional 337,396 shares in the last quarter. 87.71% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: How Do You Calculate Return on Equity (ROE)?

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.